Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 8/20 | 0.49 |
| ▸ | PYGM | P11217 | 3/20 | 0.49 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060097 | 1.00 | TK2 (0.49) | TK2PYGMTYMP | |
| SCHEMBL27179233 | 1.00 | TK2 (0.49) | TK2PYGMTYMP | |
| SCHEMBL1055729 | 0.90 | TK2 (0.47) | TK2PYGM | |
| SCHEMBL1055725 | 0.90 | TK2 (0.47) | TK2PYGM | |
| SCHEMBL6685514 | 0.89 | TK2 (0.47) | TK2PYGM | |
| SCHEMBL6685510 | 0.89 | TK2 (0.47) | TK2PYGM | |
| SCHEMBL10591532 | 0.89 | TK2 (0.54) | TK2PYGM | |
| SCHEMBL9132874 | 0.88 | TK2 (0.50) | TK2PYGMTYMP | |
| SCHEMBL9132872 | 0.88 | TK2 (0.50) | TK2PYGMTYMP | |
| SCHEMBL1417682 | 0.88 | TK2 (0.50) | TK2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727955-A1 | CYSTEINE-SUBSTITUTED RSV-F PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-12582609-B2 | Cancer vaccines | MODERNATX, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4709417-A2 | POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20050069905-A1 | Detection of molecular binding events | AGILENT TECHNOLOGIES, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040248104-A1 | Methods and reagents for profiling quantities of nucleic acids | AGILENT TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030022150-A1 | Detecting preferential bioplymers in sample; obtain nutrient broths inoculate with cells, immerse electrodes, code cells, incubate cells with substrate, monitor response, evaluate response | AGILENT TECHNOLOGIES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | disclosed |
| US-6218118-B1 | MIXTURE OF NATURAL AND MASS-MODIFIED GENERIC OLIGONUCLEOTIDE PRECURSORS; USING MIXTURE AND ENZYMATIC PROCESSES TO ALTER THE LENGTH, AND THUS THE MASS, OF PRECURSORS THAT ARE COMPLEMENTARY TO TARGET NUCLEIC ACID | AGILENT TECHNOLOGIES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1015643-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | Hewlett-Packard Company (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000003038-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | HEWLETT-PACKARD COMPANY (US) | 2000-01-20 | — | — | WO | disclosed |
| US-5459243-A | Apparatus and processes for the large scale generation and transfer of diazomethane | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, RNGTT, METTL16 | TK2 3633/4885PYGM 2866/4885TYMP 873/4885 |
| US-12582609-B2 | Cancer vaccines | RNMT, MICA, NSUN2 | TK2 2216/4885PYGM 4875/4885TYMP 2726/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | TK2 3425/4885PYGM 3025/4885TYMP 629/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK2 447/4885PYGM 2644/4885TYMP 37/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | TK2 1560/4885PYGM 4334/4885TYMP 531/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | TK2 4100/4885PYGM 3499/4885TYMP 2162/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | TK2 1499/4885PYGM 3599/4885TYMP 450/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK2 447/4885PYGM 2644/4885TYMP 37/4885 |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | PURB, DUT, NSUN2 | TK2 205/4885PYGM 3895/4885TYMP 29/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | TK2 2857/4885PYGM 3513/4885TYMP 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.